pembrolizumab

pembrolizumab is a humanized monoclonal antibody used in cancer immunotherapy. It functions as an immune checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor on lymphocytes. Developed by Merck & Co., it is marketed under the brand name Keytruda and has received approval from the U.S. Food and Drug Administration for numerous oncology indications. Its development marked a significant advancement in the treatment of various solid tumors and hematologic malignancies.

Medical uses

pembrolizumab is approved for a wide array of cancers, often following specific biomarker testing such as for microsatellite instability or PD-L1 expression. Key indications include unresectable or metastatic melanoma, non-small cell lung carcinoma, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma. It is also used in cancers of the stomach, liver, cervix, and endometrium, particularly in cases with DNA mismatch repair deficiency. The European Medicines Agency and regulatory bodies in Japan and Australia have granted similar approvals based on pivotal clinical trials like KEYNOTE-001 and KEYNOTE-006.

Adverse effects

Common adverse reactions are related to immune-mediated inflammation and include fatigue, rash, pruritus, and diarrhea. More serious immune-related adverse events can affect the lungs, liver, colon, and endocrine system, manifesting as pneumonitis, hepatitis, colitis, and hypophysitis. The risk of these events necessitates careful monitoring, as outlined in guidelines from the American Society of Clinical Oncology. Infusion-related reactions and severe skin conditions like Stevens-Johnson syndrome have also been reported in clinical studies submitted to the FDA Adverse Event Reporting System.

Mechanism of action

pembrolizumab is an IgG4 kappa immunoglobulin that binds with high affinity to the PD-1 receptor, a checkpoint protein expressed on activated T cells. By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, which are often overexpressed by tumor cells and tumor-infiltrating lymphocytes, the antibody prevents the inhibitory signal that downregulates T-cell activation. This blockade augments the endogenous anti-tumor immune response, allowing cytotoxic T cells to more effectively target and destroy malignant cells, a principle central to modern cancer immunotherapy.

History

The discovery of the PD-1 pathway is credited to researchers including Tasuku Honjo of Kyoto University, who later shared the Nobel Prize in Physiology or Medicine in 2018. pembrolizumab originated from research at Organon International and was subsequently developed by Merck & Co. following its acquisition of Schering-Plough. It received its first FDA accelerated approval in September 2014 for advanced melanoma, based on data from the KEYNOTE-001 trial. Subsequent approvals expanded its use, transforming treatment paradigms and establishing it as a foundational agent in immuno-oncology.

Society and culture

The drug is marketed globally as Keytruda by Merck & Co., known as MSD (company) outside the United States and Canada. Its high cost has sparked significant debate about healthcare economics and access within systems like the National Health Service in the United Kingdom. The therapy gained widespread public recognition when it was used to treat former U.S. President Jimmy Carter for metastatic melanoma. Its clinical success has influenced drug development strategies across the pharmaceutical industry and featured prominently in discussions at forums like the American Association for Cancer Research annual meeting.

Category:Monoclonal antibodies Category:Antineoplastic drugs Category:World Health Organization essential medicines